Analysts Expect Nu Skin Enterprises (NUS) to Post $0.89 EPS

Equities analysts expect that Nu Skin Enterprises (NYSE:NUS) will report $0.89 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Nu Skin Enterprises’ earnings, with the highest EPS estimate coming in at $0.91 and the lowest estimate coming in at $0.86. Nu Skin Enterprises posted earnings of $0.77 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 15.6%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 1st.

On average, analysts expect that Nu Skin Enterprises will report full year earnings of $3.56 per share for the current year, with EPS estimates ranging from $3.52 to $3.58. For the next fiscal year, analysts expect that the business will post earnings of $3.93 per share, with EPS estimates ranging from $3.72 to $4.27. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that cover Nu Skin Enterprises.

Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings results on Thursday, April 26th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.70 by $0.09. The business had revenue of $616.00 million for the quarter, compared to analysts’ expectations of $564.46 million. Nu Skin Enterprises had a net margin of 5.74% and a return on equity of 25.36%. The business’s quarterly revenue was up 23.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.51 EPS.

NUS has been the topic of several research analyst reports. Deutsche Bank boosted their price target on shares of Nu Skin Enterprises from $75.00 to $77.00 and gave the stock a “buy” rating in a research note on Friday, February 16th. Citigroup reiterated a “buy” rating and issued a $81.00 price target (up previously from $70.00) on shares of Nu Skin Enterprises in a research note on Tuesday, January 23rd. ValuEngine upgraded shares of Nu Skin Enterprises from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 2nd. Zacks Investment Research cut shares of Nu Skin Enterprises from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, Stifel Nicolaus boosted their price target on shares of Nu Skin Enterprises from $50.00 to $57.00 and gave the stock a “sell” rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $73.50.

NUS stock traded up $0.32 during mid-day trading on Friday, hitting $77.29. The company had a trading volume of 422,417 shares, compared to its average volume of 710,902. The stock has a market cap of $4.25 billion, a P/E ratio of 23.93, a PEG ratio of 2.57 and a beta of 1.34. Nu Skin Enterprises has a 12-month low of $76.75 and a 12-month high of $77.72. The company has a quick ratio of 0.75, a current ratio of 1.14 and a debt-to-equity ratio of 0.13.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 13th. Stockholders of record on Friday, May 25th will be issued a $0.365 dividend. The ex-dividend date is Thursday, May 24th. This represents a $1.46 dividend on an annualized basis and a dividend yield of 1.89%. Nu Skin Enterprises’s dividend payout ratio (DPR) is presently 45.20%.

In other news, General Counsel D Matthew Dorny sold 13,000 shares of the business’s stock in a transaction dated Thursday, May 3rd. The shares were sold at an average price of $73.81, for a total value of $959,530.00. Following the sale, the general counsel now directly owns 44,371 shares in the company, valued at approximately $3,275,023.51. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven Lund sold 81,000 shares of the business’s stock in a transaction dated Wednesday, April 4th. The stock was sold at an average price of $75.00, for a total transaction of $6,075,000.00. Following the completion of the sale, the chairman now owns 4,769 shares in the company, valued at $357,675. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 117,974 shares of company stock worth $8,770,066. Insiders own 5.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Cambria Investment Management L.P. increased its holdings in shares of Nu Skin Enterprises by 2.7% in the 1st quarter. Cambria Investment Management L.P. now owns 29,006 shares of the company’s stock worth $2,138,000 after buying an additional 754 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Nu Skin Enterprises by 38.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock worth $210,000 after buying an additional 858 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Nu Skin Enterprises by 7.9% in the 4th quarter. Meeder Asset Management Inc. now owns 12,830 shares of the company’s stock worth $875,000 after buying an additional 939 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of Nu Skin Enterprises by 12.0% in the 4th quarter. Bank of Montreal Can now owns 9,680 shares of the company’s stock worth $660,000 after buying an additional 1,034 shares during the last quarter. Finally, Great West Life Assurance Co. Can increased its holdings in shares of Nu Skin Enterprises by 4.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 29,888 shares of the company’s stock worth $2,203,000 after buying an additional 1,139 shares during the last quarter. Hedge funds and other institutional investors own 77.33% of the company’s stock.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply